Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13534490 | 0.86 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1EGFRGAA | |
| SCHEMBL18471564 | 0.84 | MEN1 (0.44) | MEN1KMT2AALDH1A1EGFRGAA | |
| SCHEMBL22968430 | 0.84 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1EGFRGAA | |
| SCHEMBL15491856 | 0.84 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1EGFRGAA | |
| SCHEMBL23966689 | 0.84 | MEN1 (0.44) | MEN1KMT2AALDH1A1EGFRGAA | |
| SCHEMBL23966691 | 0.84 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1EGFRGAA | |
| SCHEMBL15684071 | 0.84 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1EGFRGAA | |
| SCHEMBL12602866 | 0.84 | MAPK14 (0.41) | MEN1KMT2AALDH1A1EGFRGAA | |
| SCHEMBL9891488 | 0.84 | MEN1 (0.44) | MEN1KMT2AALDH1A1EGFRNPC1 | |
| SCHEMBL13230275 | 0.84 | MEN1 (0.44) | MEN1KMT2AALDH1A1EGFRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080051441-A1 | Aryl Sulphonamide Modulators | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| US-20070259860-A1 | MGluR5 modulators V | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259895-A1 | MGluR5 modulators VI | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259923-A1 | MGluR5 modulators IV | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | MEN1 524/4885KMT2A 4004/4885ALDH1A1 4266/4885 |
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | MEN1 4030/4885KMT2A 2904/4885ALDH1A1 4350/4885 |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | GLRA1, GRM1, GRM5 | MEN1 3361/4885KMT2A 1103/4885ALDH1A1 500/4885 |
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | MEN1 4242/4885KMT2A 2414/4885ALDH1A1 4552/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | MEN1 244/4885KMT2A 2113/4885ALDH1A1 636/4885 |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | MEN1 2749/4885KMT2A 3641/4885ALDH1A1 4521/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | MEN1 2334/4885KMT2A 3677/4885ALDH1A1 4610/4885 |
| US-20070259923-A1 | MGluR5 modulators IV | GRM5, GRM4, GRIK5 | MEN1 4353/4885KMT2A 2753/4885ALDH1A1 4471/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | MEN1 4363/4885KMT2A 3434/4885ALDH1A1 4157/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | MEN1 3254/4885KMT2A 1342/4885ALDH1A1 1427/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | MEN1 3013/4885KMT2A 2671/4885ALDH1A1 472/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | MEN1 4104/4885KMT2A 2024/4885ALDH1A1 3405/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | MEN1 1380/4885KMT2A 622/4885ALDH1A1 3764/4885 |
| US-20070259860-A1 | MGluR5 modulators V | GRM5, GRIK5, GRM2 | MEN1 4264/4885KMT2A 2629/4885ALDH1A1 4603/4885 |
| US-20070259895-A1 | MGluR5 modulators VI | GRM5, GRIK5, GRM6 | MEN1 4312/4885KMT2A 2835/4885ALDH1A1 4599/4885 |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | SDHA, SDHB, DPYD | MEN1 3100/4885KMT2A 3060/4885ALDH1A1 684/4885 |
| US-20080051441-A1 | Aryl Sulphonamide Modulators | CHRM2, CHRM1, CHRNA1 | MEN1 3032/4885KMT2A 1929/4885ALDH1A1 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.